ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Zacks #1 Rank
See how a purely mathematical analysis of earnings estimate revisions returns over 27% per year on average. Click Here to Learn More.

Quote:

Search for Ticker

Free Membership

Search:

NCST: Nucryst Pharmaceuticals Corp - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

NUCRYST PHARMACEUTICALS CORP (NASD)
NCST	1.73	N/A	(N/A%)	Vol. 0	N/A ET

Nucryst Pharmaceuticals develops, manufactures and commercializes medical products that fight infection and inflammation based on its nanocrystalline silver technology. Advanced wound care products with the company's Silcryst coatings are sold by Smith & Nephew plc under an exclusive license under its Acticoat trademark. Nucryst is also developing pharmaceutical products to address medical conditions that are characterized by both infection and inflammation. The company has developed its nanocrystalline silver in a powder form for use as an active pharmaceutical ingredient.

General Information

NUCRYST PHARMAC

50 Audubon Road Suite B Wakefield, MA 01880 Phone: 781 224-1444 Fax: 781 246-6002 Web: www.nucryst.com Email: info@nucryst.com

Industry	MED-DRUGS
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	N/A

Price and Volume Information

Zacks Rank
Yesterday's Close	1.73
52 Week High	1.74
52 Week Low	0.25
Beta	0.18
20 Day Moving Average	102,496.85
Target Price Consensus	N/A

% Price Change
4 Week	64.76
12 Week	94.38
YTD	92.22

% Price Change Relative to S&P 500
4 Week	62.98
12 Week	83.26
YTD	59.09

Share Information
Shares Outstanding (millions)	18.33
Market Capitalization (millions)	31.70
Short Ratio	0.18
Last Split Date	N/A

Dividend Information
Dividend Yield	46.24%
Annual Dividend	$0.80
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	N/A
Current Year EPS Consensus Estimate	N/A
Estimated Long-Term EPS Growth Rate	N/A
Next EPS Report Date	N/A

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	N/A
30 Days Ago	N/A
60 Days Ago	N/A
90 Days Ago	N/A

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	-%
vs. Previous Quarter	250.00%

Sales Growth
vs. Previous Year	15.74%
vs. Previous Quarter:	23.03%

Price Ratios
Price/Book	1.36
Price/Cash Flow	-
Price / Sales	1.51

ROE
09/30/09	-6.21
06/30/09	-7.34
03/31/09	-10.00

ROA
09/30/09	-5.38
06/30/09	-6.34
03/31/09	-8.83

Current Ratio
09/30/09	-
06/30/09	3.48
03/31/09	5.44

Quick Ratio
09/30/09	-
06/30/09	2.77
03/31/09	4.37

Operating Margin
09/30/09	-8.28
06/30/09	-11.40
03/31/09	-18.09

Net Margin
09/30/09	-
06/30/09	-2.79
03/31/09	-9.36

Pre-Tax Margin
09/30/09	-
06/30/09	-2.79
03/31/09	-9.36

Book Value
09/30/09	-
06/30/09	1.27
03/31/09	1.20

Inventory Turnover
09/30/09	-
06/30/09	3.16
03/31/09	3.15

Debt-to-Equity
09/30/09	-
06/30/09	0.00
03/31/09	0.00

Debt to Capital
09/30/09	-
06/30/09	0.00
03/31/09	0.00


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research